-
1دورية أكاديمية
المؤلفون: Becker, Jürgen C., Stang, Andreas, Schrama, David, Ugurel, Selma
المصدر: American Journal of Clinical Dermatology; Jul2024, Vol. 25 Issue 4, p541-557, 17p
مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, MERKEL cell carcinoma, T cells, IMMUNOTHERAPY, PROGRAMMED death-ligand 1, IMMUNE checkpoint inhibitors, CANCER chemotherapy, ADJUVANT chemotherapy, PROGRAMMED cell death 1 receptors, DRUG efficacy, COMBINED modality therapy, NIVOLUMAB, PROGRESSION-free survival, IMMUNITY, IMMUNOSUPPRESSION, OVERALL survival, IPILIMUMAB, DISEASE risk factors, CHEMICAL inhibitors
-
2دورية أكاديمية
المؤلفون: Han, Ping, Liang, Faya, Song, Pan, Wu, Taowei, Li, Yangyang, Gao, Ming, Lin, Peiliang, Fan, Jianming, Huang, Xiaoming
المصدر: Holistic Integrative Oncology; 6/27/2024, Vol. 3 Issue 1, p1-11, 11p
مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, SQUAMOUS cell carcinoma, DRUG toxicity, BIOPSY, CISPLATIN, SURVIVAL rate, DRUG side effects, LYMPHADENECTOMY, ACADEMIC medical centers, CANCER relapse, HEAD & neck cancer, PROGRAMMED death-ligand 1, IMMUNOTHERAPY, ANTINEOPLASTIC agents, PATHOLOGIC complete response, CANCER patients, RETROSPECTIVE studies, DESCRIPTIVE statistics, MANN Whitney U Test, IMMUNE checkpoint inhibitors, CANCER chemotherapy, KAPLAN-Meier estimator, THROMBOCYTOPENIA, LONGITUDINAL method, METASTASIS, COMBINED modality therapy, DRUG efficacy, FLUOROURACIL, PACLITAXEL, COMPARATIVE studies, PROGRESSION-free survival, DATA analysis software, TREATMENT delay (Medicine), OVERALL survival, NEUTROPENIA, CHEMICAL inhibitors
مصطلحات جغرافية: CHINA
-
3دورية أكاديمية
المصدر: Thoracic Cancer; Jun2024, Vol. 15 Issue 18, p1429-1436, 8p
مصطلحات موضوعية: THERAPEUTIC use of monoclonal antibodies, IN vitro studies, RESEARCH funding, KILLER cells, CHEMICAL reagents, PROGRAMMED death-ligand 1, STATISTICAL sampling, TREATMENT effectiveness, COLON tumors, MICE, IMMUNOHISTOCHEMISTRY, CYTOTOXINS, COMBINED modality therapy, ANIMAL experimentation, PROGRAMMED cell death 1 receptors, DRUG efficacy, PHOTODYNAMIC therapy, CELL survival, IMMUNE checkpoint proteins, IMMUNITY, CHEMICAL inhibitors
-
4دورية أكاديمية
المصدر: Cancers; Jun2024, Vol. 16 Issue 12, p2205, 24p
مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, DISEASE management, PROTEIN-tyrosine kinase inhibitors, IMMUNOTHERAPY, CANCER patients, COMBINED modality therapy, DNA damage, LUNG cancer, PROGRESSION-free survival, INDIVIDUALIZED medicine, GENETIC mutation, OVERALL survival
-
5دورية أكاديمية
المؤلفون: Preda, Alexandra-Cristina, Ciuleanu, Tudor-Eliade, Todor, Nicolae, Vlad, Cătălin, Iancu, Dana Ioana, Mocan, Cristina, Bandi-Vasilica, Mariana, Albu, Florina, Todor-Bondei, Irina Mihaela, Hapca, Mădălina Claudia, Kubelac, Milan-Paul, Kubelac-Varro, Adelina Dadiana
المصدر: Cancers; Jun2024, Vol. 16 Issue 11, p2022, 26p
مصطلحات موضوعية: THERAPEUTIC use of monoclonal antibodies, CANCER treatment, RESEARCH funding, IMMUNOTHERAPY, CLINICAL trials, TREATMENT effectiveness, CANCER patients, MULTIVARIATE analysis, AGE distribution, DESCRIPTIVE statistics, ADJUVANT chemotherapy, COMBINED modality therapy, DRUG efficacy, STATISTICS, LUNG cancer, NIVOLUMAB, PROGRESSION-free survival, SPECIALTY hospitals, IPILIMUMAB, OVERALL survival, EVALUATION
مصطلحات جغرافية: ROMANIA
-
6دورية أكاديمية
المصدر: Cancers; Jun2024, Vol. 16 Issue 11, p2012, 22p
-
7دورية أكاديمية
المؤلفون: Sugase, Takahito, Kanemura, Takashi, Takeoka, Tomohira, Matsuura, Norihiro, Masuike, Yasunori, Shinno, Naoki, Hara, Hisashi, Omori, Takeshi, Kitakaze, Masatoshi, Kubo, Masahiko, Mukai, Yosuke, Sueda, Toshinori, Hasegawa, Shinichiro, Akita, Hirofumi, Nishimura, Junichi, Wada, Hiroshi, Yasui, Masayoshi, Miyata, Hiroshi
المصدر: Oncology; 2024, Vol. 102 Issue 6, p484-493, 10p
مصطلحات موضوعية: THERAPEUTIC use of monoclonal antibodies, PREDICTIVE tests, IMMUNOTHERAPY, ESOPHAGEAL tumors, TREATMENT effectiveness, DESCRIPTIVE statistics, MULTIVARIATE analysis, METASTASIS, CANCER chemotherapy, LOG-rank test, PROGRAMMED cell death 1 receptors, COMBINED modality therapy, PROGRESSION-free survival, OVERALL survival
-
8دورية أكاديمية
المؤلفون: Larroquette, Mathieu, Lefort, Félix, Domblides, Charlotte, Héraudet, Luc, Robert, Grégoire, Ravaud, Alain, Gross-Goupil, Marine
المصدر: Cancers; May2024, Vol. 16 Issue 9, p1780, 15p
-
9دورية أكاديمية
المؤلفون: Li, Yang, Deng, Guodong, Liang, Ning, Hu, Pingping, Zhang, Yan, Qiao, Lili, Zhang, Yingying, Xie, Jian, Luo, Hui, Wang, Fei, Chen, Fangjie, Liu, Fengjun, Xu, Deguo, Zhang, Jiandong
المصدر: Oncology; 2024, Vol. 102 Issue 5, p382-398, 17p
مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, MEDICAL information storage & retrieval systems, PATIENT safety, RADIATION pneumonitis, STATISTICAL significance, RESEARCH funding, IMMUNOTHERAPY, CHEMORADIOTHERAPY, TREATMENT effectiveness, META-analysis, DESCRIPTIVE statistics, SYSTEMATIC reviews, MEDLINE, COMBINED modality therapy, MEDICAL databases, LUNG cancer, ONLINE information services, PROGRESSION-free survival, TUMOR classification, CONFIDENCE intervals, DATA analysis software, OVERALL survival, REGRESSION analysis
-
10دورية أكاديمية
المؤلفون: Bachelard, Antoine, Hingrat, Quentin Le, Ferré, Valentine-Marie, Lê, Minh, Peytavin, Gilles, Damond, Florence, Charpentier, Charlotte, Goudot, Guillemette Fremont, Bouille, Jeanne Goupil de, Lariven, Sylvie, Delobel, Pierre, Yazdanpanah, Yazdan, Descamps, Diane, Matheron, Sophie, Ghosn, Jade, group, for the ANRS CO05 VIH-2 cohort study
المصدر: Clinical Infectious Diseases; 4/15/2024, Vol. 78 Issue 4, p1005-1010, 6p
مصطلحات موضوعية: THERAPEUTIC use of monoclonal antibodies, KIDNEY function tests, PATIENT compliance, VIRAL load, RESEARCH funding, SALVAGE therapy, SCIENTIFIC observation, DRUG resistance in microorganisms, CD4 lymphocyte count, MULTIDRUG resistance, HIV infections, TREATMENT effectiveness, BLOOD cell count, DESCRIPTIVE statistics, ANTIVIRAL agents, COMBINED modality therapy, RESEARCH, BLOOD plasma, ANTI-HIV agents, DRUGS, GENETIC mutation, TIME, LIVER function tests, DRUG tolerance